You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Arcus Biosciences closes $138M IPO
Global Capital Markets & SPAC Activity – H1 2021
Gauging Supply Chain Risk In Volatile Times
Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals
The Future of Risk Management Digitization in Credit Risk Management
Arcus Biosciences Inc. closed its IPO of 8 million common shares priced at $15 apiece to raise $138 million in gross proceeds.
The underwriters fully exercised their overallotment option to buy an additional 1.2 million shares.
Citigroup, Goldman Sachs & Co. LLC and Leerink Partners acted as joint book-running managers for the offering.